MedTrace Logo

Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy Phase II

NCT04201353 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1984

Last updated 2024-08-19

No results posted yet for this study

Summary

This protocol describes a 2-arm cluster, randomized controlled trial designed to test the effectiveness of a conditional cash transfer on viral suppression at 12 months post-ART initiation among PHWHIV who have initiated ART within the past 30 days. Randomization will take place at the clinic level (HIV primary care clinics), and eligible participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (\~$10) each, conditional on visit attendance with the HIV care provider. The study will take place at 32 clinics across four regions in Tanzania: Gaeta, Mwanza, Kagera and Shinyanga. The primary endpoint is viral suppression at 12 months, defined as the proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 12 months after starting ART.

Conditions

  • HIV (Human Immunodeficiency Virus)

Interventions

BEHAVIORAL

Conditional Cash Transfer

The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (\~$10) for up to 6 months conditional on visit attendance.

Sponsors & Collaborators

  • Health for a Prosperous Nation

    collaborator OTHER

  • Rasello

    collaborator INDUSTRY

  • Tanzania Ministry of Health, Community Development, Gender, Elderly and Children

    collaborator UNKNOWN

  • University of California, Berkeley

    lead OTHER

Principal Investigators

  • Sandra McCoy, PhD · University of California, Berkeley

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-09
Primary Completion
2023-11-10
Completion
2024-06-30

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04201353 on ClinicalTrials.gov